Bitolterol

Identification

Name
Bitolterol
Accession Number
DB00901  (APRD00827)
Type
Small Molecule
Groups
Withdrawn
Description

Bitolterol mesylate is a beta-2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001. [Wikipedia]

Structure
Thumb
Synonyms
  • Bitolterol Mesylate
  • Bitolterolum
International/Other Brands
Tornalate
Categories
UNII
9KY0QXD6LI
CAS number
30392-40-6
Weight
Average: 461.5494
Monoisotopic: 461.220223107
Chemical Formula
C28H31NO5
InChI Key
FZGVEKPRDOIXJY-UHFFFAOYSA-N
InChI
InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
IUPAC Name
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate
SMILES
CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C

Pharmacology

Indication

Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Pharmacodynamics

Bitolterol, an adrenergic bronchodilator, is a prodrug that widens constricted airways in the lungs by relaxing the smooth muscles that surround the bronchial passages. Bitolterol probably does not affect the inflammation in the lung, such as in bronchitis. Bitolterol is unique in that it is a prodrug because it must first be metabolized by the body before it becomes active.

Mechanism of action

Bitolterol is an adrenergic beta-2 agonist. Asthma results from a narrowing of the bronchial tubes. This narrowing is caused by muscle spasm and inflammation within the bronchial tubes. Agonism of the beta-2 adrenergic receptors by bitolterol leads to a relaxation of the smooth muscles surrounding these airway tubes which then increases the diameter and ease of air flow through the tubes.

TargetActionsOrganism
ABeta-2 adrenergic receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Bitolterol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
AcepromazineAcepromazine may decrease the vasoconstricting activities of Bitolterol.Approved, Vet Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Bitolterol.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Bitolterol.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Bitolterol.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Bitolterol.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bitolterol.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Bitolterol.Approved, Illicit, Investigational
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
AsenapineAsenapine may decrease the vasoconstricting activities of Bitolterol.Approved
AtenololAtenolol may decrease the bronchodilatory activities of Bitolterol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Bitolterol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Bitolterol is combined with Atosiban.Approved, Investigational
AzosemideBitolterol may increase the hypokalemic activities of Azosemide.Investigational
BendroflumethiazideBitolterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bitolterol.Withdrawn
BenzthiazideBitolterol may increase the hypokalemic activities of Benzthiazide.Approved
Benzylpenicilloyl PolylysineBitolterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Bitolterol can be decreased when used in combination with Betahistine.Approved, Investigational
BetaxololBetaxolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
BevantololBevantolol may decrease the vasoconstricting activities of Bitolterol.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Bitolterol.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Bitolterol.Approved
BrexpiprazoleBrexpiprazole may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Bitolterol.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Bitolterol.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Bitolterol.Investigational
BumetanideBitolterol may increase the hypokalemic activities of Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Bitolterol.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Bitolterol.Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Bitolterol.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Bitolterol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Bitolterol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Bitolterol.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
ChlorothiazideBitolterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineChlorpromazine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational, Vet Approved
ChlorthalidoneBitolterol may increase the hypokalemic activities of Chlorthalidone.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bitolterol.Approved, Investigational, Vet Approved
CloranololCloranolol may decrease the bronchodilatory activities of Bitolterol.Experimental
ClozapineClozapine may decrease the vasoconstricting activities of Bitolterol.Approved
CyclopenthiazideBitolterol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DapiprazoleDapiprazole may decrease the vasoconstricting activities of Bitolterol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Bitolterol.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Bitolterol.Approved, Investigational
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Bitolterol.Approved, Illicit
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Bitolterol.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Bitolterol.Approved, Investigational
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Bitolterol.Approved, Withdrawn
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Bitolterol.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Bitolterol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Bitolterol.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Doxofylline is combined with Bitolterol.Approved, Investigational
DronedaroneDronedarone may decrease the vasoconstricting activities of Bitolterol.Approved
DroperidolDroperidol may decrease the vasoconstricting activities of Bitolterol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Bitolterol.Approved
EpinephrineEpinephrine may decrease the vasoconstricting activities of Bitolterol.Approved, Vet Approved
EpitizideBitolterol may increase the hypokalemic activities of Epitizide.Experimental
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Bitolterol.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Bitolterol.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Bitolterol.Approved
EscitalopramEscitalopram may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Bitolterol.Approved
Etacrynic acidBitolterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FlupentixolFlupentixol may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational, Withdrawn
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bitolterol.Approved, Investigational, Vet Approved
FurosemideBitolterol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Bitolterol.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Bitolterol.Experimental
HydrochlorothiazideBitolterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBitolterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
IloperidoneIloperidone may decrease the vasoconstricting activities of Bitolterol.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Bitolterol.Approved
IndapamideBitolterol may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Bitolterol.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Bitolterol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bitolterol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bitolterol.Approved
LabetalolLabetalol may decrease the vasoconstricting activities of Bitolterol.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Bitolterol.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Bitolterol.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Bitolterol.Withdrawn
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Bitolterol.Experimental, Investigational
MepindololMepindolol may decrease the bronchodilatory activities of Bitolterol.Experimental
MethotrimeprazineMethotrimeprazine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
MethyclothiazideBitolterol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Bitolterol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Bitolterol.Approved
MetolazoneBitolterol may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Bitolterol.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Bitolterol.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bitolterol.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Bitolterol.Approved
NebivololNebivolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
NefazodoneNefazodone may decrease the vasoconstricting activities of Bitolterol.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Bitolterol.Withdrawn
NicardipineNicardipine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
NicergolineNicergoline may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
NiguldipineNiguldipine may decrease the vasoconstricting activities of Bitolterol.Experimental
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Bitolterol.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bitolterol.Withdrawn
OlanzapineOlanzapine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Bitolterol.Investigational
OxprenololOxprenolol may decrease the bronchodilatory activities of Bitolterol.Approved
PaliperidonePaliperidone may decrease the vasoconstricting activities of Bitolterol.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Bitolterol.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bitolterol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Bitolterol.Withdrawn
PhenoxybenzaminePhenoxybenzamine may decrease the vasoconstricting activities of Bitolterol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Bitolterol.Withdrawn
PhentolaminePhentolamine may decrease the vasoconstricting activities of Bitolterol.Approved
PindololPindolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
PiretanideBitolterol may increase the hypokalemic activities of Piretanide.Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Bitolterol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Bitolterol.Withdrawn
PizotifenPizotifen may decrease the vasoconstricting activities of Bitolterol.Approved
PolythiazideBitolterol may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Bitolterol.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Bitolterol.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bitolterol.Approved, Investigational
PromazinePromazine may decrease the vasoconstricting activities of Bitolterol.Approved, Vet Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Bitolterol.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
PropranololPropranolol may decrease the bronchodilatory activities of Bitolterol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bitolterol.Approved
QuetiapineQuetiapine may decrease the vasoconstricting activities of Bitolterol.Approved
QuinethazoneBitolterol may increase the hypokalemic activities of Quinethazone.Approved
QuinidineQuinidine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Bitolterol.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bitolterol.Approved
RisperidoneRisperidone may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Bitolterol.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Bitolterol.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Bitolterol.Approved
SotalolSotalol may decrease the bronchodilatory activities of Bitolterol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Bitolterol.Approved
TamsulosinTamsulosin may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Bitolterol.Approved
TertatololTertatolol may decrease the bronchodilatory activities of Bitolterol.Experimental
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Bitolterol.Approved
ThioridazineThioridazine may decrease the vasoconstricting activities of Bitolterol.Approved, Withdrawn
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Bitolterol.Approved, Investigational
TimololTimolol may decrease the bronchodilatory activities of Bitolterol.Approved
TolazolineTolazoline may decrease the vasoconstricting activities of Bitolterol.Approved, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Bitolterol.Approved
TorasemideBitolterol may increase the hypokalemic activities of Torasemide.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bitolterol.Approved, Investigational
TrazodoneTrazodone may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
TrichlormethiazideBitolterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
TrimazosinTrimazosin may decrease the vasoconstricting activities of Bitolterol.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bitolterol.Approved
UrapidilUrapidil may decrease the vasoconstricting activities of Bitolterol.Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bitolterol.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Bitolterol.Approved
VerapamilVerapamil may decrease the vasoconstricting activities of Bitolterol.Approved
ZiprasidoneZiprasidone may decrease the vasoconstricting activities of Bitolterol.Approved
ZuclopenthixolZuclopenthixol may decrease the vasoconstricting activities of Bitolterol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Bierman CW, Kemp JP, Nathan RA: Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 1996 Jan;76(1):27-35. [PubMed:8564625]
  2. Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. [PubMed:3278878]
  3. Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP: Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy. 1994 Mar;72(3):209-16. [PubMed:8129213]
  4. Messina MS: Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. Adv Ther. 1995 May-Jun;12(3):157-63. [PubMed:10155050]
External Links
KEGG Drug
D00684
KEGG Compound
C06853
PubChem Compound
35330
PubChem Substance
46506895
ChemSpider
32525
ChEBI
3133
ChEMBL
CHEMBL1201295
PharmGKB
PA448644
Drugs.com
Drugs.com Drug Page
Wikipedia
Bitolterol
ATC Codes
R03AC17 — Bitolterol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
Packagers
  • Pharmedix
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00048 mg/mLALOGPS
logP4.69ALOGPS
logP6.3ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)14ChemAxon
pKa (Strongest Basic)9.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.86 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity132.76 m3·mol-1ChemAxon
Polarizability50.91 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8753
Blood Brain Barrier-0.9679
Caco-2 permeable-0.7805
P-glycoprotein substrateSubstrate0.7533
P-glycoprotein inhibitor IInhibitor0.5438
P-glycoprotein inhibitor IINon-inhibitor0.7643
Renal organic cation transporterNon-inhibitor0.9069
CYP450 2C9 substrateNon-substrate0.7406
CYP450 2D6 substrateNon-substrate0.771
CYP450 3A4 substrateNon-substrate0.5086
CYP450 1A2 substrateNon-inhibitor0.8381
CYP450 2C9 inhibitorNon-inhibitor0.8987
CYP450 2D6 inhibitorNon-inhibitor0.8594
CYP450 2C19 inhibitorNon-inhibitor0.9
CYP450 3A4 inhibitorNon-inhibitor0.7754
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8853
Ames testNon AMES toxic0.9151
CarcinogenicityNon-carcinogens0.8648
BiodegradationNot ready biodegradable0.9876
Rat acute toxicity2.3906 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9912
hERG inhibition (predictor II)Non-inhibitor0.7982
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Depsides and depsidones
Sub Class
Not Available
Direct Parent
Depsides and depsidones
Alternative Parents
Benzoic acid esters / Phenol esters / Phenoxy compounds / Benzoyl derivatives / Aralkylamines / Toluenes / Dicarboxylic acids and derivatives / Amino acids and derivatives / Carboxylic acid esters / 1,2-aminoalcohols
show 6 more
Substituents
Depside backbone / Benzoate ester / Phenol ester / Benzoic acid or derivatives / Phenoxy compound / Benzoyl / Aralkylamine / Toluene / Monocyclic benzene moiety / Dicarboxylic acid or derivatives
show 19 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
diester, carboxylic ester, secondary alcohol, secondary amino compound, ethanolamines (CHEBI:3133)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wilson AJ, Gibson PG, Coughlan J: Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev. 2000;(2):CD001281. [PubMed:10796631]
  4. Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. [PubMed:3278878]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:26